Eleni Frangou

7PUBLICATIONS
35CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersDisease surveillanceMedical infection agents (incl. prions)Intensive care
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Sep 21, 2026
Health-related quality of life with adjuvant immune checkpoint inhibition in renal cell carcinoma: A qualitative study of UK participants in the phase III RAMPART trial.

|Apr 16, 2026
Multiplexed P21/MCM-2 Detection Predicts Relapse and May Identify Tyrosine Kinase Inhibitor-Resistant Patients in Clear Cell Renal Cell Carcinoma.

|Feb 10, 2026
QT prolongation risk factors and a monitoring strategy in rifampicin-resistant tuberculosis: Findings from the STREAM Stage 2 trial.

Gareth Hughes, Elena Frangou, Henry Bern

|Aug 02, 2025
Brain Imaging and Whole Blood Targeted Transcriptomic Analyses to Characterize Cerebral Infarctions in Children With Tuberculous Meningitis.

Julie Huynh, Pieter M Pretorius, Wajanat Jan

|Feb 25, 2022
External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer.

Bhavna Oza, Tim Eisen, Eleni Frangou

|Oct 14, 2020
Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial.

Tim Eisen, Eleni Frangou, Bhavna Oza

Pageof 2

Frequent Collaborators

3 joint publications

James Larkin

3 joint publications

Grant D Stewart

2 joint publications

Mahesh K B Parmar

2 joint publications

Steven Joniau